US Patent

US10226436 — Norepinephrine compositions and methods therefor

Method of Use · Assigned to Nevakar Inc · Expires 2038-01-30 · 12y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects compositions and methods for ready-to-inject norepinephrine with improved stability.

USPTO Abstract

The inventive subject matter is directed to compositions and methods for ready-to-inject norepinephrine compositions with improved stability. Most preferably, compositions presented herein are substantially antioxidant free and exhibit less than 10% isomerization of R-norepinephrine and exhibit less than 5% degradation of total norepinephrine.

Drugs covered by this patent

Levophed (Norepinephrine Bitartrate) · Pfizer Inc.

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3461`	—	Levophed
`U-3461`	—	Levophed
`U-3461`	—	Levophed

Patent Metadata

Patent number: US10226436
Jurisdiction: US
Classification: Method of Use
Expires: 2038-01-30
Drug substance claim: No
Drug product claim: Yes
Assignee: Nevakar Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.